Bicara Therapeutics Inc. (NASDAQ:BCAX) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) have earned a consensus recommendation of “Buy” from the eight brokerages that are covering the firm, MarketBeat.com reports. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $41.20.

BCAX has been the subject of several research reports. Wedbush reaffirmed an “outperform” rating and issued a $31.00 target price on shares of Bicara Therapeutics in a research report on Wednesday. Rodman & Renshaw started coverage on Bicara Therapeutics in a research note on Tuesday, November 5th. They issued a “buy” rating and a $48.00 price objective for the company. HC Wainwright lifted their price objective on Bicara Therapeutics from $42.00 to $45.00 and gave the company a “buy” rating in a research note on Monday, January 27th. Finally, RODMAN&RENSHAW upgraded Bicara Therapeutics to a “strong-buy” rating in a research note on Tuesday, November 5th.

Bicara Therapeutics Price Performance

Shares of NASDAQ:BCAX opened at $13.12 on Friday. The business’s 50-day simple moving average is $15.27. Bicara Therapeutics has a 12-month low of $11.10 and a 12-month high of $28.09.

Bicara Therapeutics (NASDAQ:BCAX) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($1.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.46) by ($1.14). On average, sell-side analysts forecast that Bicara Therapeutics will post -2.59 EPS for the current year.

Institutional Investors Weigh In On Bicara Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. Spire Wealth Management purchased a new stake in Bicara Therapeutics during the fourth quarter worth approximately $31,000. Legal & General Group Plc purchased a new stake in Bicara Therapeutics during the fourth quarter worth approximately $33,000. Ameritas Investment Partners Inc. purchased a new stake in Bicara Therapeutics during the fourth quarter worth approximately $35,000. Cinctive Capital Management LP lifted its stake in Bicara Therapeutics by 88.7% during the fourth quarter. Cinctive Capital Management LP now owns 16,984 shares of the company’s stock worth $296,000 after purchasing an additional 7,983 shares during the last quarter. Finally, SG Americas Securities LLC purchased a new stake in Bicara Therapeutics during the fourth quarter worth approximately $147,000.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.